ImetelChat

Could also be why Geron slow walking combination AML study

Ryan so true. When blast crisis ensues it just a tsunami. As far as timing of the Gilead study cessation I doubt Geron’s LR MDS study has little or no impact since there as yet is virtually no clinical AML or higher risk MDS data with Imetelstat. The magro study failed without any help from Geron. I...

If the Imetelstat high risk MDS/AML studies are fruitful, it’s hard to see where immediate competition comes from. Clearly an area with no recent new therapies. Here is a brief summary of where CAR-t is in MDS and the hurdles presented. Doesn’t look like there is too much there in the immediate futu...

Like I said, it’s difficult to translate just ask a German.

LWS, your definition is way too extreme. It’s much more subtle then that.

Little doubt that Geron’s value did increase by some number with this event.

Kmall, re CAR-t, I still can’t get a handle on its potential use in MF and MDS. Besides expense and an older target population, it appears that some patients who get CAR-t for other indications actually have some risk of developing myeloproliferative diseases post therapy.

Hi Ryan, thanks for posting. The M at least in the past was for minimal but maybe the nomenclature has changed. As to schadenfreude, it is a great word with no real translation into english and experiencing it leads to embarrassment and self flagellation. Mea Culpa.

Kmall, totally agree. This finding was completely unexpected giving the studies leading up to the PIII. I had an aha moment several years ago when listening to a lecture where an expert made the off hand comment that CRs did not necessarily correspond to improvements in OS. Hence the continued inter...

I am a little bit astounded by this announcement, especially since the 1b study showed a 31% CR rate. That preliminary study was not blinded like the PIII magro study. End point OS. As the search for effective heme treatments goes on, the field narrows. Not good news for patients who have so few opt...

Good question. It may be that Geron now has the in house staff to take over responsibilities that were previously contracted out to Parexel but that is just speculation.

Correctamundo. Gwickly, find a comfortable chair.

Wishful thinking. Geron hasn’t even made the 50% enrollment mark for MF study

RC try this
https://events.q4inc.com/attendee/256492434

Jingle I meant a race to receive first line designation no question Geron has the upper hand

RC listen again, it seemed to me that he misspoke and meant Imetelstat

It means it’s a race

Nope.

It’s a little hard to know how patients who qualify for compassionate use actually get the drug. Geron is not a well known philanthropic institution, that is to say it is highly unlikely they are going to give the stuff out for free and third party reimbursement is probably not established for a dru...